Discontinued — last reported Q4 '23
Humana Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost increased by 5.0% to $7.06B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.0%, from $7.59B to $7.06B. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates higher exposure to complex, non-standard debt instruments which may carry higher prepayment or duration risk.
This represents the amortized cost of available-for-sale debt securities that do not have a single, fixed maturity date,...
Standard disclosure for insurance companies managing complex investment portfolios.
other_available_for_sale_securities_debt_maturities_with_06797b| Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $7.87B | $7.88B | $7.36B | $7.62B | $7.88B | $7.59B | $7.41B | $6.73B | $7.06B |
| QoQ Change | — | +0.1% | -6.6% | +3.5% | +3.4% | -3.7% | -2.4% | -9.2% | +5.0% |
| YoY Change | — | — | -6.4% | -3.3% | — | +3.2% | -2.8% | -14.7% | -7.0% |